Bicentenary of An Account of the Foxglove. Historical address given at Edgbaston Parish Church, Birmingham.

Whitfield, A. G. W.

doi:10.1136/hrt.54.3.253

The platform will undergo maintenance on Sep 14 at about 9:30 AM EST and will be unavailable for approximately 1 hour.

Heart

1985

DOI: 10.1136/hrt.54.3.253

|View full text |Cite

Bicentenary of An Account of the Foxglove. Historical address given at Edgbaston Parish Church, Birmingham.

A. G. W. Whitfield¹

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

1986

1993

Publication Types

Select...

Article4

Relationship

Self Cite0

Independent4

Authors

Journals

Cited by 4 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…That jour ney took place in 1775 and 10 years later William Withering published his book 'An Account of the Foxglove' [1]. The 200th an niversary of the publication of that book was celebrated in 1985 and many articles ap peared describing the life and times of this famous scientist and physician [2][3][4], Whit field [5] in an address delivered at Edgbaston Parish Church (William Withering lived in Edgbaston Hall) whilst appreciating the bril liance of the man also acknowledged his shortcomings. Whitfield wrote: 'He was cer tainly a difficult colleague, prickly and quar relsome, and if he knew any amusing stories he kept them to himself.…”

mentioning

confidence: 99%

Digitalis: Dead or Alive?

Poole‐Wilson¹

1988

Cardiology

View full text Add to dashboard Cite

Over 200 years age, William Withering described the advantages which might be gained by the considered use of extracts of the foxglove, digitalis purpurea, in patients with congestive heart failure, particularly if the rhythm was irregular. In the subsequent years many patients undoubtedly benefited from the use of this drug. The introduction of diuretics in the present century provided an alternative, more effective and safer treatment for heart failure. More recently, angiotensin-converting enzyme inhibitors have become available. The use of digoxin in the treatment of heart failure is now indicated almost solely for the control of a fast heart rate in patients with atrial fibrillation.

show abstract

mentioning

confidence: 99%

Digitalis: Dead or Alive?

Poole‐Wilson¹

1988

Cardiology

View full text Add to dashboard Cite

show abstract

Digoxin?A redundant drug in congestive cardiac failure

Poole‐Wilson

Robinson

1989

Cardiovasc Drug Ther

View full text Add to dashboard Cite

Controversy continues concerning the use of digoxin as a positive inotropic agent in the treatment of heart failure in patients in sinus rhythm. Digoxin is properly used to control the heart rate in patients in atrial fibrillation. The findings from 14 uncontrolled and 6 controlled clinical trials have been examined. Digoxin does exert a small chronic positive inotropic effect. Although some individual patients, particularly those with fluid overload, appear to benefit from digoxin, controlled clinical trials in patients, most of whom have been treated with diuretics, have failed to demonstrate an increase of exercise capacity. No mortality trial has been attempted. Digoxin has the potential to be harmful in patients with ischemic heart disease. Alternative and safer therapies have been shown to be equal or superior to digoxin.

show abstract

Digoxin is effective, but is it safe?

Marcus

1993

Cardiovasc Drug Ther

View full text Add to dashboard Cite

In the last 15 years several double-blind, placebo-controlled clinical trials have unequivocally shown that digitalis decreases symptoms of cardiac failure, results in a reduction in the need for hospitalization for treatment of congestive heart failure, and improves cardiac function. The major unresolved question concerning digitalis use is its safety. There are experimental data and clinical evidence that digitalis use may be associated with an increased mortality, particularly in the first year or two after an acute myocardial infarction. This increased mortality appears to be present even after adjustment for predictor covariants. This conclusion depends on the ability of statistical methods to account for differences in comorbidity. Since the question of digitalis safety remains after myocardial infarction, the physician should carefully examine the indications for administration of digitalis. More than the usual surveillance is required during chronic digitalis administration.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Bicentenary of An Account of the Foxglove. Historical address given at Edgbaston Parish Church, Birmingham.

Cited by 4 publications

References 0 publications

Digitalis: Dead or Alive?

Digitalis: Dead or Alive?

Digoxin?A redundant drug in congestive cardiac failure

Digoxin is effective, but is it safe?

Contact Info

Product

Resources

About